Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Eyal C. Attar Sells 15,968 Shares of Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Eyal C. Attar sold 15,968 shares of Aprea Therapeutics stock in a transaction on Thursday, September 16th. The shares were sold at an average price of $4.68, for a total transaction of $74,730.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ:APRE opened at $4.85 on Tuesday. The company has a 50-day moving average price of $4.39 and a 200-day moving average price of $4.70. Aprea Therapeutics, Inc. has a 12 month low of $3.17 and a 12 month high of $30.99. The stock has a market cap of $102.76 million and a price-to-earnings ratio of -2.16.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, August 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). On average, equities research analysts expect that Aprea Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

A number of research firms have weighed in on APRE. Royal Bank of Canada dropped their target price on shares of Aprea Therapeutics from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research note on Friday, August 13th. Morgan Stanley lowered shares of Aprea Therapeutics from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $5.00 to $3.00 in a report on Thursday, August 12th. Zacks Investment Research lowered shares of Aprea Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 4th. HC Wainwright dropped their price target on shares of Aprea Therapeutics from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Monday, August 16th. Finally, Berenberg Bank cut shares of Aprea Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research report on Monday, August 16th. Two analysts have rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.15.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC lifted its position in Aprea Therapeutics by 2,725.9% during the 1st quarter. SG Americas Securities LLC now owns 655,888 shares of the company’s stock valued at $3,345,000 after acquiring an additional 632,678 shares during the period. Morgan Stanley lifted its position in Aprea Therapeutics by 111.0% during the 1st quarter. Morgan Stanley now owns 998,127 shares of the company’s stock valued at $5,090,000 after acquiring an additional 525,106 shares during the period. Walleye Trading LLC lifted its position in Aprea Therapeutics by 7.4% during the 1st quarter. Walleye Trading LLC now owns 41,254 shares of the company’s stock valued at $210,000 after acquiring an additional 2,854 shares during the period. UBS Asset Management Americas Inc. bought a new stake in Aprea Therapeutics during the 1st quarter valued at about $116,000. Finally, Voloridge Investment Management LLC bought a new stake in Aprea Therapeutics during the 1st quarter valued at about $1,551,000. 30.73% of the stock is owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers.

Recommended Story: Trading Ex-Dividend Strategy

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.